Experienced in Bronchiolitis Obliterans

Dr. John F. Kingrey

Pulmonary Medicine | Intensive Care Medicine
Integris Cardiovascular Physicians LLC
3400 Nw Expressway, Suite 300, 
Oklahoma City, OK 
Accepting New Patients
Offers Telehealth
Experienced in Bronchiolitis Obliterans
Integris Cardiovascular Physicians LLC
3400 Nw Expressway, Suite 300, 
Oklahoma City, OK 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Kingrey is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Oklahoma City, Oklahoma. Dr. Kingrey is rated as an Experienced provider by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Lung Metastases, Endoscopy, and Advanced Bronchoscopy. Dr. Kingrey is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Bronchiolitis Obliterans.

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in OH
Hospital Affiliations
Integris Health Edmond Hospital
Integris Baptist Medical Center, Inc
Ascension St John Medical Center
Integris Southwest Medical Center
Languages Spoken
English
French
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

INTEGRIS CARDIOVASCULAR PHYSICIANS LLC
3400 Nw Expressway, Suite 300, Oklahoma City, OK 73112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: June 10, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
Enrollment Status: Active_not_recruiting
Publish Date: March 28, 2025
Intervention Type: Drug
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
View 8 Less Clinical Trials

7 Total Publications

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study.
Journal: Advances in therapy
Published: April 17, 2025
Similar Doctors
Advanced in Bronchiolitis Obliterans
Dr. Michael S. Hull
Pulmonary Medicine
Advanced in Bronchiolitis Obliterans
Dr. Michael S. Hull
Pulmonary Medicine

Ou Health Partners Inc

900 Ne 10th St, Ouhp Family Medicine, 
Oklahoma City, OK 
 (5.7 miles away)
405-271-4311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Hull is a Pulmonary Medicine provider in Oklahoma City, Oklahoma. Dr. Hull is rated as a Distinguished provider by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, Bronchiectasis, and Gastrostomy. Dr. Hull is currently accepting new patients.

Advanced in Bronchiolitis Obliterans
Dr. Brad A. Marion
Pulmonary Medicine
Advanced in Bronchiolitis Obliterans
Dr. Brad A. Marion
Pulmonary Medicine
6205 N Santa Fe Ave, Suite 201, 
Oklahoma City, OK 
 (3.7 miles away)
405-272-8338
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Marion is a Pulmonary Medicine provider in Oklahoma City, Oklahoma. Dr. Marion is rated as a Distinguished provider by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Lung Metastases, Sarcoidosis, Bronchitis, and Chronic Obstructive Pulmonary Disease (COPD). Dr. Marion is currently accepting new patients.

Advanced in Bronchiolitis Obliterans
Dr. Sergio G. Garcia
Pulmonary Medicine | Emergency Medicine | Intensive Care Medicine
Advanced in Bronchiolitis Obliterans
Dr. Sergio G. Garcia
Pulmonary Medicine | Emergency Medicine | Intensive Care Medicine

Norman Regional Providers Specialty Care

3400 W Tecumseh Rd, 300 Neurology Assoc Ok Hea, 
Norman, OK 
 (19.2 miles away)
405-307-5700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Sergio Garcia is a Pulmonary Medicine specialist and an Emergency Medicine provider in Norman, Oklahoma. Dr. Garcia is rated as a Distinguished provider by MediFind in the treatment of Bronchiolitis Obliterans. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Lung Nodules, and Bronchiectasis. Dr. Garcia is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kingrey's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile